Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# National Lipid Association: Enhance the science and practice of lipidology and promote optimal cardiometabolic health.

## Sitemaps
[XML Sitemap](https://www.lipid.org/sitemap_index.xml): Includes all crawlable and indexable pages.

## Pages
- [Lipid Specialist](https://www.lipid.org/lipid-specialist/): The Lipid Specialist crosses specialty boundaries to assist in detecting and treating these disorders. Diagnosis and treatment of these complex patients involve knowledge and use of advanced diagnostics and the utilization of complex disease management strategies; these include therapeutic interventions such as diet, exercise, lifestyle, complex pharmacotherapy, occasionally plasma exchange and/or apheresis, and often utilize a multidisciplinary team approach.
- [The New Dyslipidemia Paradigm Month One](https://www.lipid.org/new-dyslipidemia-paradigm-month-one/): Month One · Available Now
- [NLA Series  From Cholesterol to Dyslipidemia](https://www.lipid.org/nla-series-from-cholesterol-to-dyslipidemia/): Webinar & Podcast Series
- [The Child with Extreme LDL-C](https://www.lipid.org/the-child-with-extreme-ldl-c/): Enduring Internet Activity
- [familial-hypercholesterolemia-certificates](https://www.lipid.org/familial-hypercholesterolemia-certificates/): Thank you for listening to the NLA's Evolving Standards in Familial Hypercholesterolemia: Innovations in Diagnosis and Therapeutic Strategies podcast. Select the appropriate certificate below then type in your name and print or save a copy for your records.
- [Evolving Standards in Familial Hypercholesterolemia Accreditation Information](https://www.lipid.org/lipidinsights/s7e1accreditation/): PROGRAM OVERVIEW:
- [Beef and Cardiovascular Disease Podcast Certificate Download](https://www.lipid.org/lipidinsights/s6e8certificates/): Thank you for listening to the NLA's Beef and Cardiovascular Disease podcast. Select the appropriate certificate below then type in your name and print or save a copy for your records.
- [Beef and Cardiovascular Disease Podcast Accreditation Information](https://www.lipid.org/lipidinsights/s6e8baccreditation/): PROGRAM OVERVIEWBeef and Cardiovascular Disease: What the Science Says Podcast
- [NLA Conferences: Frequently Asked Questions](https://www.lipid.org/nla-conferences-frequently-asked-questions/): The NLA hosts two signature educational conferences each year:
- [About the National Lipid Association: Frequently Asked Questions](https://www.lipid.org/about-the-national-lipid-association-frequently-asked-questions/): The National Lipid Association (NLA) is a professional medical society dedicated to advancing the science and clinical practice of lipidology — the study of cholesterol, triglycerides, and other lipids, and their role in cardiovascular disease. The NLA brings together physicians, advanced practice providers, pharmacists, dietitians, nurses, and other healthcare professionals who share a commitment to improving patient outcomes through better prevention, detection, and treatment of lipid disorders.
- [Regist](https://www.lipid.org/conferences-2026-fall-clinical-lipid-update-registration/)
- [The Lipid Panel Certificates](https://www.lipid.org/lipid-panel-certificates/): Thank you for joining the NLA's Lipid Panel webcast. Select the appropriate certificate below. You can then type in your name and print or save a copy for your records.
- [Lipid Scholarship Program](https://www.lipid.org/lipid-scholarship-program/): Lipid Scholars receive exclusive access to resources, mentoring, and opportunities for career advancement, including:
- [Self-Assessment Program](https://www.lipid.org/programs/self-assessment-program/): Program Overview
- [Making LDL Make Sense](https://www.lipid.org/programs/making-ldl-make-sense/): A CME/CE Webinar and Enduring Activity
- [CaseCare360](https://www.lipid.org/programs/casecare360/): ACTIVITY TYPEEnduring Internet
- [Prioritizing Lp(a) Screening](https://www.lipid.org/programs/prioritizing-lpa-screening/): Prioritizing Lp(a) Screening and LDL-C Lowering to Transform Cardiovascular Risk Across the ASCVD Continuum
- [Staff](https://www.lipid.org/about-us/staff/): About Us
- [Lipidology Learning Pathway](https://www.lipid.org/education/): NLA Education & Certification
- [Virtual Learning](https://www.lipid.org/virtual-learning/): Virtual Learning
- [Master of the NLA (MNLA)](https://www.lipid.org/about-us/awards/master-of-the-nla-mnla/): NLA Awards
- [Fellow of the NLA](https://www.lipid.org/about-us/awards/fellow-of-the-nla-award/): NLA Awards
- [The NLA Honorary Lifetime Membership Award](https://www.lipid.org/about-us/awards/honorary-lifetime-member-of-the-nla/): NLA Awards
- [Foundation of the NLA Clinician/Educator Award](https://www.lipid.org/about-us/awards/foundation-of-the-nla-clinician-educator-award/): NLA Awards
- [The W. Virgil Brown Distinguished Achievement Award & Lectureship](https://www.lipid.org/about-us/awards/the-w-virgil-brown-distinguished-achievement-award/): NLA Awards
- [Awards & Scholarships](https://www.lipid.org/about-us/awards/): NLA Awards
- [Practice Tools](https://www.lipid.org/practice-tools/): About Us
- [Regional Chapters](https://www.lipid.org/about-us/regional-chapters/): About Us
- [Leadership](https://www.lipid.org/about-us/leadership/): About Us
- [Terms of Service](https://www.lipid.org/terms-of-service/): lipid.org and its constituent sites form a peer to peer and top-down service that allows members to create unique personal profiles online in order to communicate and exchange scientific thought and how to organize practice activities within the worldwide community of lipidology. The web based service is operated by the National Lipid Association (NLA) and the domain www.lipid.org is owned by the NLA. By using the Website you agree to be bound by these Terms of Use (this "Agreement"), whether or not you register as a member ("Member") of the NLA. If you wish to make use of the services (the "Service"), please read this Agreement and indicate your acceptance by following the instructions in the Registration process.
- [Access to Therapy](https://www.lipid.org/access-to-therapy/): The NLA aims to provide its members with relevant information on therapies for lipid disorders and the barriers to using certain therapies in order to raise the standard of clinical lipidology and in turn provide enhanced care for patients. The NLA authors articles and creates practical tools to provide guidance on identifying the right patients for the right therapies and practical approaches to eliminate the associated barriers of use.
- [The NLA Staff](https://www.lipid.org/contact-us/staff/): National Lipid Associationc/o Compass Management & Consulting, Inc. | 12574 Flagler Center Blvd | Suite 101 | Jacksonville, FL 32258 Phone: (904) 998-0854
- [Industry Council](https://www.lipid.org/about-us/industry-council/): The National Lipid Association gratefully recognizes our 2026 Industry Council members for their support of education, research, professional development, and initiatives that advance patient care.
- [Award](https://www.lipid.org/award/): The 2026 Fellow of the NLA nomination window will be open from September 15 - December 15, 2025.
- [Bylaws & Policies](https://www.lipid.org/about-us/bylaws-and-policies/): About Us
- [History & Mission](https://www.lipid.org/about/): About Us
- [Knowledge Center](https://www.lipid.org/knowledge-center/): NLA Resources
- [404](https://www.lipid.org/404/)
- [Topics](https://www.lipid.org/topics/): NLA Resources
- [Contact Us](https://www.lipid.org/contact-us/): National Lipid Association
- [Join NLA](https://www.lipid.org/join-nla/): Membership
- [About Us](https://www.lipid.org/about-us/): About Us
- [Privacy Policy](https://www.lipid.org/privacy-policy/): Suggested text: Our website address is: https://www.lipid.org.
- [National Lipid Association](https://www.lipid.org/): Welcome to the

## Resources
- [Lipoprotein(a) Management Simplified](https://www.lipid.org/resource/lipoproteina-management-simplified-clinician-infographic/)
- [Lipoprotein(a) Management Simplified: The National Lipid Association Lipid Simplified Series](https://www.lipid.org/resource/lipoproteina-management-simplified-the-national-lipid-association-lipid-simplified-series/): This document aims to provide practical guidance on testing and management of Lp(a) for primary and secondary ASCVD risk management.
- [National Lipid Association Highlights New Meta-Analysis Supporting LDL-C Lowering in Primary Prevention](https://www.lipid.org/resource/national-lipid-association-highlights-new-meta-analysis-supporting-ldl-c-lowering-in-primary-prevention/): The National Lipid Association (NLA) today announced the publication of a new meta-analysis evaluating the impact of low-density lipoprotein cholesterol (LDL-C) lowering on major adverse cardiovascular events (MACE) in primary prevention populations. The study synthesizes data from randomized trials of both statin and non-statin therapies and updates a landmark 2012 analysis conducted by the Cholesterol Treatment Trialists’ Collaboration (CTTC).
- [Dietary Patterns & Nutrition Interventions for Individuals with Dyslipidemia](https://www.lipid.org/resource/dietary-patterns-nutrition-interventions-for-individuals-with-dyslipidemia/): The mission of the National Lipid Association (NLA) is “to enhance the science and practice of lipidology and promote optimal cardiometabolic health.” The NLA leadership acknowledges the publication of the 2025-2030 Dietary Guidelines for Americans (DGAs), which are used to inform dietary guidance and nutrition policies for the general population. The NLA leadership believes the publication of the DGAs provides an opportunity to reaffirm the dietary patterns and nutrition interventions recommended by the NLA for adults and children living with dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), and cardiometabolic risk factors.
- [US Food and Drug Administration Approves LIB Therapeutics’ LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol](https://www.lipid.org/resource/us-food-and-drug-administration-approves-lib-therapeutics-lerochol-lerodalcibep-liga-for-adults-with-elevated-ldl-cholesterol/): CINCINNATI, Ohio – December 15, 2025 – LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S. Food and Drug Administration (FDA) has approved LEROCHOL™ (lerodalcibep-liga) injection for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
- [Amgen Makes Repatha® Available Through AmgenNow, A Direct-to-patient Program in the US](https://www.lipid.org/resource/amgen-makes-repatha-available-through-amgennow-a-direct-to-patient-program-in-the-us/): THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.
- [REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C](https://www.lipid.org/resource/repatha-now-indicated-for-adults-at-increased-risk-for-major-adverse-cardiovascular-events-due-to-uncontrolled-ldl-c/): THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.' The update removes a prior requirement for a patient to have been diagnosed with cardiovascular (CV) disease.
- [NLA and FNLA Urge CMS and Administrator Oz to Include Low-Density Lipoprotein Cholesterol (LDL-C) Measurement in CMS Quality Measurement Programs](https://www.lipid.org/resource/nla-and-fnla-urge-cms-and-administrator-oz-to-include-low-density-lipoprotein-cholesterol-ldl-c-measurement-in-cms-quality-measurement-programs/): JACKSONVILLE, Fla., May 19, 2025/PRNewswire/ -- The National Lipid Association (NLA) and Foundation of the National Lipid Association (Foundation) urge the Centers for Medicare & Medicaid Services (CMS) and recently confirmed CMS Administrator, Dr. Mehmet C. Oz, to help increase measurement and management of low-density lipoprotein cholesterol (LDL-C) through CMS quality measurement programs. Effective LDL-C management is essential to addressing atherosclerotic cardiovascular disease (ASCVD) — the United States' leading cause of death. Following more than 40 years of decline, death related to ASCVD has been on the rise for over a decade, accompanied by decreased rates of LDL-C measurement and accompanying CMS incentives.
- [National Lipid Association Releases Expert Clinical Review on Familial Chylomicronemia Syndrome (FCS)](https://www.lipid.org/resource/national-lipid-association-releases-expert-clinical-review-on-familial-chylomicronemia-syndrome-fcs/): The National Lipid Association (NLA) has released a comprehensive clinical review titled “Familial Chylomicronemia Syndrome: An Expert Clinical Review from the National Lipid Association.” This new guidance provides an in-depth examination of the diagnosis, management, and treatment landscape for familial chylomicronemia syndrome (FCS) — a rare and severe genetic disorder characterized by extremely high triglyceride levels (≥ 1,000 mg/dL) and an elevated risk of life-threatening recurrent acute pancreatitis.
- [National Lipid Association and American Society for Preventive Cardiology Release Joint Expert Consensus on Chylomicronemia Management](https://www.lipid.org/resource/national-lipid-association-and-american-society-for-preventive-cardiology-release-joint-expert-consensus-on-chylomicronemia-management/): The National Lipid Association (NLA), in collaboration with the American Society for Preventive Cardiology (ASPC), has released a Joint Expert Clinical Consensus providing new guidance on the recognition and management of persistent chylomicronemia — a severe and often misunderstood form of hypertriglyceridemia. The full paper is now published in the Journal of Clinical Lipidology and available here.
- [Novartis Receives FDA Approval for Label Update On Use of Leqvio (Inclisiran)](https://www.lipid.org/resource/novartis-receives-fda-approval-for-label-update-on-use-of-leqvio-inclisiran/): Novartis received FDA approval for a label update that will allow for use of Leqvio ® (inclisiran) in certain patients at high risk of cardiovascular (CV) disease. This broader population allows for earlier Leqvio treatment in patients with elevated low-density lipoprotein cholesterol (LDL-C) and CV risk factors, such as diabetes and hypertension, who are at increased risk of atherosclerotic cardiovascular disease (ASCVD), beyond the previously approved ASCVD and heterozygous familial hypercholesterolemia (HeFH) patient population.
- [Ionis Receives FDA Approval for TRYNGOLZA (Olezarsen) for Adults with FCS](https://www.lipid.org/resource/ionis-receives-fda-approval-for-tryngolza-olezarsen-for-adults-with-fcs/): On December 19, 2024, Ionis Pharmaceuticals, Inc. received FDA approval for TRYNGOLZA (Olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly.
- [Statin-Drug Interactions](https://www.lipid.org/resource/statin-drug-interactions/)
- [S7E10: Fresh from Munich: Plozasiran and the SHASTA-3 & SHASTA-4 Trial Results](https://www.lipid.org/resource/s7e10-fresh-from-munich-plozasiran-and-the-shasta-3-shasta-4-trial-results/): Hot off the European Society of Cardiology Congress in Munich, this Lipid Insights episode takes a closer look at a significant announcement in triglyceride science and its implications for clinical practice. Host Peter H. Jones, MD, MNLA sits down with Christie M. Ballantyne, MD, MNLA to discuss the 12-month pivotal trial results from SHASTA-3 and SHASTA-4 — evaluating plozasiran in patients with severe hypertriglyceridemia. If you missed Munich, this is your catch-up.
- [Industry Innovations | Episode 7: A New Era for FCS: Diagnosis, Daily Life & the Science That’s Changing Everything](https://www.lipid.org/resource/industry-innovations-episode-7-a-new-era-for-fcs-diagnosis-daily-life-the-science-thats-changing-everything/): Familial chylomicronemia syndrome (FCS) is one of the rarest and most challenging lipid disorders to manage, but the landscape is changing rapidly. In this Industry Innovations episode, guest host Kevin Maki, PhD, CLS, MNLA sits down with Archna Bajaj, MD, FNLA for a comprehensive and forward-looking conversation on FCS from every angle.
- [S7E9: HDL Under the Microscope: Setting the Record Straight with Dr. Lipid](https://www.lipid.org/resource/s7e9-hdl-under-the-microscope-setting-the-record-straight-with-dr-lipid/): In this Lipid Insights episode, host Peter H. Jones, MD, MNLA sits down with Thomas Dayspring, MD, FACP, MNLA — widely known as "Dr. Lipid" — for a deep dive into one of lipidology's most complex and frequently misrepresented topics: HDL-Cholesterol.
- [Top Line Results from the Phase 3 Lp(a)HORIZON Trial](https://www.lipid.org/resource/top-line-results-from-the-phase-3-lpahorizon-trial/): On September 4, 2026, Novartis announced the topline results of its phase 3 Lp(a)HORIZON trial. Novartis shared that while pelacarsen lowered lipoprotein(a) levels, the trial failed to reduce the risk of major adverse cardiovascular events (MACE). The Lp(a)HORIZON trial enrolled 8,323 patients with elevated Lp(a) and established atherosclerotic cardiovascular disease (ASCVD) to assess whether pelacarsen (an antisense oligonucleotide targeting the apolipoprotein(a) mRNA) reduces the risk of a cardiovascular event in this population. The full clinical trial results are not yet available, but may yield further insight into treatment effect.
- [Make Your Voice Heard: Support LDL-C Quality Measurement in the CMS CY 2027 Physician Fee Schedule](https://www.lipid.org/resource/make-your-voice-heard-support-ldl-c-quality-measurement-in-the-cms-cy-2027-physician-fee-schedule/): The Centers for Medicare & Medicaid Services (CMS) is accepting public comments on the Calendar Year (CY) 2027 Medicare Physician Fee Schedule Proposed Rule, and clinicians, patients, caregivers, and cardiovascular health advocates have an important opportunity to make their voices heard. Comments must be submitted by September 14, 2026.
- [Industry Innovations | Episode 6: Guidelines in Action](https://www.lipid.org/resource/episode-6-industry-innovations-guidelines-in-action/): The guidelines exist. The evidence is clear. So why does the gap between what we know and what we do in practice persist? In this Industry Innovations episode, guest host Daniel E. Soffer, MD, MNLA sits down with Nihar R. Desai, MD, MPH, FNLA and Jessica M. Pena, MD, MPH, FNLA to tackle one of the most pressing challenges in cardiovascular medicine: implementation.
- [ICD-10 Codes for Lipid Management](https://www.lipid.org/resource/icd-10-codes/): ICD-10
- [Industry Innovations | Episode 5: Statin Intolerance in Focus: Navigating Side Effects, Patient Concerns, and the Path to Optimal LDL Lowering](https://www.lipid.org/resource/episode-5-statin-intolerance-in-focus-navigating-side-effects-patient-concerns-and-the-path-to-optimal-ldl-lowering/): When two past NLA Presidents and seasoned podcast hosts sit down together, the conversation is bound to be something special. In this Industry Innovations episode, Peter H. Jones, MD, MNLA is joined by fellow lipidologist Alan S. Brown, MD, MHA, MNLA for an in-depth discussion on one of the most clinically nuanced topics in lipid management: statin intolerance.
- [S7E8: Thinking Long-Term: LDL Exposure, Longevity Medicine, and the Future of Cardiovascular Prevention](https://www.lipid.org/resource/s7e8-thinking-long-term-ldl-exposure-longevity-medicine-and-the-future-of-cardiovascular-prevention/): How do we move the needle on cardiovascular prevention — not just in the clinic, but across entire systems and communities? In this episode of Lipid Insights, host Alan S. Brown, MD, MHA, MNLA sits down with Nihar R. Desai, MD, MPH, FNLA for a forward-thinking conversation on long-term LDL exposure and what it truly means to practice longevity medicine.
- [The Lipid Panel – A Case of Elevated Lp(a) in Secondary Prevention](https://www.lipid.org/resource/the-lipid-panel-a-case-of-elevated-lpa-in-secondary-prevention-mar-2023/): https://www.youtube.com/watch?v=NlGae5gaZQk&list=PL8nKM3Ic838zjbsJFZGHMXP39ow6zj6Xq&index=30
- [The Lipid Panel – Adolescent with Combined Hyperlipidemia and Elevated Transaminases](https://www.lipid.org/resource/the-lipid-panel-adolescent-with-combined-hyperlipidemia-and-elevated-transaminases-jun-2023/): https://www.youtube.com/watch?v=GUdXwjK-m0w&list=PL8nKM3Ic838zjbsJFZGHMXP39ow6zj6Xq&index=28\
- [The Lipid Panel – Inflammatory Diseases](https://www.lipid.org/resource/the-lipid-panel-inflammatory-diseases-oct-2023/): https://www.youtube.com/watch?v=Xmym5jTydfY&list=PL8nKM3Ic838zjbsJFZGHMXP39ow6zj6Xq&index=26
- [The Lipid Panel – Update on LDL-lowering Medications](https://www.lipid.org/resource/the-lipid-panel-update-on-ldl-lowering-medications-may-2024/): https://www.youtube.com/watch?v=Z6XvtfQeLvA&list=PL8nKM3Ic838zjbsJFZGHMXP39ow6zj6Xq&index=19
- [The Lipid Panel – Less-Common Dyslipidemias](https://www.lipid.org/resource/the-lipid-panel-less-common-dyslipidemias-jun-2024/): https://www.youtube.com/watch?v=T_Dw4AXlnCQ&list=PL8nKM3Ic838zjbsJFZGHMXP39ow6zj6Xq&index=18
- [The Lipid Panel – Unique Lipid Cases ApoE, Apolipo-proteins, Low HDL](https://www.lipid.org/resource/the-lipid-panel-unique-lipid-cases-apoe-apolipo-proteins-low-hdl-sep-2024/): https://www.youtube.com/watch?v=ZiQeCTELqN4&list=PL8nKM3Ic838zjbsJFZGHMXP39ow6zj6Xq&index=17
- [The Lipid Panel – Diabetes and ASCVD Risk](https://www.lipid.org/resource/the-lipid-panel-diabetes-and-ascvd-risk-jan-2025/): https://www.youtube.com/watch?v=3hDQA-4sTIM&list=PL8nKM3Ic838zjbsJFZGHMXP39ow6zj6Xq&index=14&t=3179s
- [The Lipid Panel – Imaging: Inside the Plaque](https://www.lipid.org/resource/the-lipid-panel-imaging-inside-the-plaque-mar-2026/): https://www.youtube.com/watch?v=BCq2iqxAkMU&list=PL8nKM3Ic838zjbsJFZGHMXP39ow6zj6Xq&index=3&t=205s
- [CAC Scoring](https://www.lipid.org/resource/cac-scoring-mar-2022/): https://www.youtube.com/watch?v=z50PFLV7j8s&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=31&t=113s
- [Pediatric Hypercholesterolemia](https://www.lipid.org/resource/pediatric-hypercholesterolemia-nov-2023/): https://www.youtube.com/watch?v=RsE6mpTEpTM&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=14
- [Practical Tips on Testosterone Replacement Therapy](https://www.lipid.org/resource/practical-tips-on-testosterone-replacement-therapy-dec-2023/): https://www.youtube.com/watch?v=PYN3VcPz6vs&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=13
- [Risk of Dementia](https://www.lipid.org/resource/risk-of-dementia-may-2024/): https://www.youtube.com/watch?v=m05uxT5g1nU&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=7&t=68s
- [Lowering ASCVD Events by Treating Residual Inflammatory Risk – Discussion of Low Dose Colchicine](https://www.lipid.org/resource/lowering-ascvd-events-by-treating-residual-inflammatory-risk-discussion-of-low-dose-colchicine/): https://www.youtube.com/watch?v=MBf1Pcbu62I&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=5&t=1s
- [Leveraging the Power of Coronary CTA to Guide Primary Prevention Treatment in ASCVD](https://www.lipid.org/resource/leveraging-the-power-of-coronary-cta-to-guide-primary-prevention-treatment-in-ascvd-oct-2024/): https://www.youtube.com/watch?v=Da4qfv2yClg&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=4&t=11s
- [More Than Just a Script: Treating the Whole Patient](https://www.lipid.org/resource/more-than-just-a-script-treating-the-whole-patient/): https://www.youtube.com/watch?v=HTyBOkiBoBQ&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=1&t=1505s
- [Working with Patients Following Very-Low Carbohydrate and/or Ketogenic Diets](https://www.lipid.org/resource/working-with-patients-following-very-low-carbohydrate-and-or-ketogenic-diets-oct-2021/): https://www.youtube.com/watch?v=jOqV3YRAYBs&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=32
- [Cutting Edges in the Lipid World](https://www.lipid.org/resource/cutting-edges-in-the-lipid-world-mar-2023/): https://www.youtube.com/watch?v=gz_frjrC7u4&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=30
- [Dietary Nutrition](https://www.lipid.org/resource/dietary-nutrition-mar-2023/): https://www.youtube.com/watch?v=BwuMuMVIb8k&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=29
- [Tour of Lipid Disorders- From Basics to Disease](https://www.lipid.org/resource/tour-of-lipid-disorders-from-basics-to-disease-mar-2023/): https://www.youtube.com/watch?v=Enwm3N5cZLM&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=28
- [Lp(a) Today & Tomorrow](https://www.lipid.org/resource/lpa-today-tomorrow-mar-2023/): https://www.youtube.com/watch?v=Jt0arIhQe50&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=27
- [Obesity Therapy: Role for GLP-1 Agonists](https://www.lipid.org/resource/obesity-therapy-role-for-glp-1-agonists-mar-2023/): https://www.youtube.com/watch?v=Zp5RfK42Y-Q&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=26
- [Exploring the Paradox of High HDL Cholesterol](https://www.lipid.org/resource/exploring-the-paradox-of-high-hdl-cholesterol-mar-2023/): https://www.youtube.com/watch?v=hxLrsBurg0Q&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=25
- [NAFLD/NASH](https://www.lipid.org/resource/nafld-nash-apr-2023/): https://www.youtube.com/watch?v=4tm-aprSzOg&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=24
- [Statin Intolerance: A Vexing and Elusive Clinical Problem](https://www.lipid.org/resource/statin-intolerance-a-vexing-and-elusive-clinical-problem-apr-2023/): https://www.youtube.com/watch?v=1yW5VBKll00&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=23
- [ApoE – What Lipidologists Need to Know and What They Were Never Taught](https://www.lipid.org/resource/apoe-what-lipidologists-need-to-know-and-what-they-were-never-taught-may-2023/): https://www.youtube.com/watch?v=acEtPS_R300&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=22
- [Inflammation & Atherosclerosis – Where have we been? Where are we going?](https://www.lipid.org/resource/inflammation-atherosclerosis-where-have-we-been-where-are-we-going-may-2023/): https://www.youtube.com/watch?v=KiY_v9MeS7c&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=21
- [Prevention of AD: What the Lipidologist Needs to Know](https://www.lipid.org/resource/prevention-of-ad-what-the-lipidologist-needs-to-know-jun-2023/): https://www.youtube.com/watch?v=6cbGudVT-Tc&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=20
- [Cardiovascular Imaging Use to Assess Risk](https://www.lipid.org/resource/cardiovascular-imaging-use-to-assess-risk-jul-2023/): https://www.youtube.com/watch?v=GJin01G_dQc&list=PL8nKM3Ic838xu-1FJYMHUXbS7MbvvYRO5&index=19

## Courses
- [Masters In Lipidology](https://www.lipid.org/courses/masters-in-lipidology/)
- [Foundations of Lipidology](https://www.lipid.org/courses/foundations-of-lipidology/)
- [Mastering Triglycerides](https://www.lipid.org/courses/mastering-triglycerides/)

## Conferences
- [Fall SP](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/agenda/fall-sp/)
- [Special Events](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/special-events/): The Fall Clinical Lipid Update offers more than exceptional education and cutting-edge clinical insights. Throughout the meeting, attendees have opportunities to connect, recharge, and create memorable experiences alongside colleagues, faculty, industry partners, and friends.
- [Confirmed Sponsors](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/exhibitors-sponsors/confirmed-sponsors/): The National Lipid Association gratefully acknowledges the organizations supporting the 2026 Fall Clinical Lipid Update. Their participation helps support meaningful education, networking, and attendee experiences for the lipid community.
- [Exhibitor Resources](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/exhibitors-sponsors/exhibitor-resources/): Thank you for supporting the 2026 NLA Fall Clinical Lipid Update. This section includes the key forms, deadlines, exhibit hall schedule, and onsite planning resources sponsors and exhibitors need to prepare for a successful meeting experience.
- [Become a Sponsor](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/exhibitors-sponsors/become-a-sponsor/): The NLA Fall Clinical Lipid Update offers exhibitors and sponsors direct access to healthcare professionals seeking practical, clinically relevant education in lipid management, preventive cardiology, and cardiovascular risk reduction. Whether your goal is to build awareness, showcase innovation, support attendee experience, or create deeper conversations with faculty and clinicians, NLA provides flexible opportunities to support your objectives.
- [Exhibitors & Sponsors](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/exhibitors-sponsors/): Join the National Lipid Association for the 2026 Fall Clinical Lipid Update, where clinicians, educators, researchers, and industry partners come together to advance lipid management, cardiovascular risk reduction, and patient care.
- [Registration](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/registration/): Registration is open for the 2026 NLA Clinical Lipid Update. Before beginning registration, please review the options below to select the experience that best fits your plans.
- [Accreditation](https://www.lipid.org/conferences/scientific-sessions/accreditation/): PROGRAM OVERVIEW:
- [Become a Social Media Ambassador](https://www.lipid.org/conferences/become-a-social-media-ambassador/): The 2026 #NLASessions Media Ambassador Program empowers NLA's next generation of lipidologists — fellows-in-training, residents, associate members, and LSP recipients — to amplify NLA's mission, grow our digital presence, and bring the energy of the Scientific Sessions to a wider audience.
- [Social Media Toolkit](https://www.lipid.org/conferences/social-media-toolkit/): June 11-14, 2026Sheraton Grand Chicago Riverwalk
- [Engage](https://www.lipid.org/conferences/scientific-sessions/engage/)
- [Become a Sponsor](https://www.lipid.org/conferences/sponsorship/become-a-sponsor/): June 11-14 | Chicago, IL
- [Sponsorship](https://www.lipid.org/conferences/sponsorship/)
- [Pre-Conference Courses](https://www.lipid.org/conferences/scientific-sessions/pre-conference-courses/): OFFERED IN-PERSON ONLY
- [Special Events](https://www.lipid.org/conferences/scientific-sessions/special-events/): Kick off the NLA Scientific Sessions with our Opening Night Kickoff Reception in the Exhibit Hall. Right after the Opening Session, jump into the action—explore the exhibits, connect with our supporters, and mingle with colleagues while enjoying a lively atmosphere and a chance to win raffle prizes. Before you head to our evening dinner symposium or out to dinner, make this the first stop of your evening.
- [Venue](https://www.lipid.org/conferences/scientific-sessions/venue/): The 2026 NLA Scientific Sessions will be held at the Sheraton Grand Chicago Riverwalk
- [Faculty](https://www.lipid.org/conferences/scientific-sessions/program/faculty/): President-Elect, National Lipid AssociationProfessor and Chief of CardiologyDirector of Lipid Clinic and Advanced Cardiac ImagingUniversity of Louisville Louisville, KY
- [Satellite Symposia](https://www.lipid.org/conferences/scientific-sessions/program/satellite-symposia/): This continuing education activity is provided by the National Lipid Association.Educational Partner: Vindico Medical Education
- [Flash Forums](https://www.lipid.org/conferences/scientific-sessions/program/flash-forums/): Flash Forums are short, high energy educational sessions held in the Exhibit Hall during peak breaks at the meeting. Designed for quick engagement, these programs deliver focused insights in a fast paced, easy to attend format while you’re exploring the hall.
- [Expert Theater](https://www.lipid.org/conferences/scientific-sessions/expert-theater/): Expert Theaters are industry supported, non CME educational sessions held during designated breaks in the official meeting schedule. These focused programs feature thought leaders and clinical experts who dive into timely topics in lipid management, cardiovascular risk reduction, and emerging therapies.
- [Agenda](https://www.lipid.org/conferences/scientific-sessions/program/agenda/): 2026 #NLASessions Agenda  Thursday, June 11, 2026 3:00 - 3:50 PMExpert Theater | Sponsored by Chiesi Global Rare Disease | Snack provided by the NLASession Title Coming Soon3:00 - 3:50 PMExpert Theater | Sponsored by Heartflow | Snack provided by the NLARedefining Risk: Leveraging CCTA and Plaque Analysis for Personalized Cardiovascular Prevention 4:00 - 6:00 PMSession I | 2026 Opening Session“Lower for Longer”: Advancing Lipid Management in the Era of Evolving Evidence and 2026 Guideline Updates*Co-hosted with the National Lipid Association and VindicoCME This fast‑paced program begins with an engaging, evidence‑based overview of newly updated guidelines and key clinical trial findings. From there, you’ll dive into real‑world case challenges that explore primary, moderate‑risk, and high‑risk patient scenarios. Through integrated audience polling, you’ll actively test your knowledge and decision‑making on topics such as risk assessment, LDL‑C and Lp(a) management, therapy selection, and treatment escalation.Expert faculty will walk you through each case, break down the most relevant data, and translate emerging evidence into practical, actionable strategies you can apply immediately in your clinical practice.By the end of this session, you’ll feel more confident applying current guidelines, evaluating new and emerging therapies, and supporting team‑based approaches to improving cardiovascular outcomes.*Subject to change based on funding approval. 6:00 - 7:00 PMOpening Night Exhibit Hall Kickoff Reception  Friday, June 12, 2026 | Decoding Discovery: From Global Mechanism to Patient Medicine 6:45 - 8:45 AM CME Situation Room: Exploring the Cardiovascular and Neurocognitive Implications of CETP InhibitionHosted by Vindico Medical EducationThis is an independent satellite CME/CE symposium held in conjunction with the NLA 2026 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.8:00 - 9:00 AMBreakfast in Exhibit Hall 9:00 - 10:30 AMSession II | From Genetic Discovery to Clinical ActionCRISPR-Based Gene Editing: Rewriting the Code for Lifetime Lipid Control and Cardiovascular Prevention   Ashish Sarraju, MDGenotype-Informed Prevention: The Economic Case for Cascade Screening in Familial Hypercholesterolemia   William Weintraub, MDUnlocking the Future of Cardiology: The Next Generation of Therapies Driven by Genetic Discovery  David Davidson, MD 10:30 - 11:00 AM Abstract Author Q&A  10:40 - 10:55 AMFlash Forum | Exhibit Hall | Sponsored by Mirum PharmaceuticalsSession Title Coming Soon 11:00 - 11:20 AMNLA Incoming President's Address11:20 AM - 12:00 PM W. Virgil Brown Distinguished Achievement Award LectureshipMy Journey as a Researcher, Clinician, and Patient in the Field of Lipids and Atherosclerosis: Setbacks, Advances, and Opportunities ChristieBallantyne, MD12:00 - 12:20 PM NLA Scientific Updates  12:25 - 1:15 PMExpert Theater | Sonsored by Ionis Pharmaceuticals | Lunch provided by the NLATRYNGOLZA: proven results and real-patient experiences12:25 - 1:15 PMExpert Theater | Sponsored by Kaneka - LIPOSORBER | Lunch provided by the NLASession Title Coming Soon 12:20 - 1:20 PM Lunch in Exhibit Hall 1:20 - 1:50 PMSession III | Late Breakers 1:50 - 2:20 PM Abstract Author Q&A 2:00 - 2:15 PMFlash Forum | Exhibit Hall | Sponsored by AllelicaSession Title Coming Soon 2:20 - 3:50 PMSession IV | Severe Hypertriglyceridemia: A Comprehensive Exploration of Uncommon Causes and Emerging InsightsPersistent Chylomicronemia, Looking Beyond FCS   Zahid Ahmad, MD, FNLA  GPIHBP1 Autoantibody Syndrome Explained   Katsuyuki Nakajima, PhDThe Adipose Deficit: Recognizing Lipodystrophy as a Cause of Severe HTG   Vinaya Simha MBBS, MD 3:50 - 4:20 PM Abstract Author Q&A 4:20 - 6:05 PMSession V | NLA/EAS Joint SessionPrimary Prevention of ASCVD: a Joint Session from the European Atherosclerosis Society and the National Lipid AssociationPrimary Prevention & Lp(a): The Updated Guidelines   Bø​rge Nordestgaard, MD, DMScUsing Imaging to Augment Primordial and Primary Prevention   Dinesh Kalra, MD, FNLACombination Drug Therapy to Achieve Guideline Goals   Kausik Ray, MD, FMedSciHow Do We Improve Implementation?   Kaye-Eileen Willard, MD, FNLA  Saturday, June 13, 2026 | Legacy, Data, and the Next Generation of Care 8:00 - 8:50 AMExpert Theater | Sponsored by Arrowhead Pharmaceuticals, Inc. | Breakfast provided by the NLASession Title Coming Soon8:00 - 8:50 AMExpert Theater | Sponsored by Regeneron | Breakfast provided by the NLAUncover HoFH, an ultra-rare lipid disorder, and Explore EVKEEZA (evinacumab-dgnb) as a treatment option 8:00 - 9:00 AMBreakfast in Exhibit Hall 9:00 - 10:30 AMSession VI | Rewriting the Rules for Primary Prevention: New Outcomes from Intensive LDL-C Reduction in High-Risk PatientsThe Original PCSK9 Inhibitor Trials: FOURIER, ODYSSEY Outcomes, FOURIER OLE   Bob Giugliano, MDWhat We've Learned about LDL-C and Outcomes   Nicholas Marston, MDVESALIUS-CV   Erin Bohula, MD, DPhil 10:30 - 11:00 AM Abstract Author Q&A 10:40 - 10:55 AMFlash Forum | Exhibit Hall | Sponsored by Alexion Pharmaceuticais-AstraZeneca Rare DiseaseLysosomal Acid Lipase Deficiency (LAL-D) Disease Overview 11:00 AM - 12:30 PMSession VII | Abstract Award WinnersNLA Business MeetingHunninghake Familial Hypercholesterolemia (FH) Award:  Early Detection of Familial Hypercholesterolemia Through Point of Care Testing in 2-Year-Olds  Jose Lopez, MS3rd Place Award: Pooled Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, Across Two Phase 3 Trials: CORALreef Lipids and CORALreef HeFH   Christie Ballantyne, MD2nd Place Award: Accelerating Lipoprotein(a) Testing in Community Health Centers Through Quality Improvement and Education  Jeremy Skinner, BS1st Place Award:  GLP-1 Receptor Agonists Rarely Cause Acute Pancreatitis but Induce Noninflammatory Acinar Hypertrophy, Pancreatic Enlargement and Mild Lipase Leak   Jianing Li, MD 12:35 - 1:25 PMExpert Theater | Sponsored by Amgen | Lunch provided by the NLASession Title Coming Soon12:35 - 1:25 PMExpert Theater | Sponsored by Ionis Pharmaceuticals | Lunch provided by the NLASevere Hypertriglyceridemia (sHTG)An Underrecognized, Life-Threatening Disease 12:30 - 1:30 PM Lunch in Exhibit Hall 1:30 - 2:35 PMSession VIII | Young Investigator Award Winners5th Place Award: Real World Experience with ApoC-III Inhibition in Patients with Persistent Chylomicronemia  Kamil Winnicki, MD4th Place Award: 21-Oxo-Docosanoic Acid, a Fatty Acid ω-Oxidation–Derived Metabolite, Predicts Non-Mild Acute Pancreatitis: Evidence from Longitudinal Metabolomics   Yonghao Chen, MD3rd Place Award: Treatment-Adjusted Phenotyping and Ascertainment Bias Correction Enable Accurate Familial Hypercholesterolemia Diagnosis: The TUDOR Algorithm   Nadar Genedy, MBBS, MRCP2nd Place Award: Opportunistic cardiometabolic risk detection in young blood donors  David Lee, MD1st Place Award: Lipid-Related Polygenic Risk Score and Its Association with Coronary Artery Calcification  Tomoyo Hamana, MD, PhD 2:35 - 2:50 PM Break  2:50 - 4:00 PMSession IX | Lipid Scholarship Program Case Discussions 4:00 - 4:15 PMBreak 4:15 - 5:45 PMSession X | Managing the Child's Trajectory: Intervening on Early Cardiometabolic RiskA Generation at Risk: Understanding and Mitigating Insulin Resistance in Youth   Jeanie Tryggestad, MD   Pre-Atherosclerotic Imaging in Pediatrics: Capturing Early Cardiovascular Risk   Justin Zachariah, MDNurturing the Next Generation: A Family Affair of Health   Preneet Cheema Brar, MD, MS 5:45 - 6:05 PMNLA: A Historical Perspective   Ernst Schaefer, MD, FNLA 6:30 - 7:45 PM NLA Honors and Awards Ceremony  Sunday, June 14, 2026 | Systems in Flux: Redefining Risk and Resilience 8:00 - 9:00 AMBreakfast 9:00 - 10:30 AMSession XI | Deciphering Women's Risk: New Perspectives on Lipids, Pre-eclampsia, and Navigating HRT in Cardiometabolic HealthWhen Pregnancy Predicts Heart Health: The Critical Role of Lipids in Pre-eclampsia  Tara Nowakthar, DOFrom Caution to Clarity: Re-evaluating the Risk-Benefit Profile of HRT after the FDA Policy Shift  Rachel Novik, DOTeam-Based Care of Women with Cardiovascular Disease: From Pre-Conception Through Pregnancy and Postpartum  Brittany Katz, MD 10:30 - 10:45 AMBreak 10:45 AM - 12:15 PMSession XII | Inflammation: The GI, Metabolic and Renal LinkLipoprotein(a): The Genetic Inflammatory Fuel Driving Total Cardiovascular Risk   Michael Shapiro, DOThe Role of Non-Invasive Imaging in Assessing MASLD-Related Inflammation and Fibrosis  Kathleen Wyne, MD, PhDModulating the Gut Microbiome: A Novel Strategy for Attenuating Inflammation and Reducing Cardiorenal Risk   Michelle Routhenstein, MS, RD, CDCES, CDN 12:15 PMAdjourn
- [Program](https://www.lipid.org/conferences/scientific-sessions/program/)
- [Venue](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/venue/): 14900 Chelonia PkwyOrlando, FL 32821(407) 919-6300 | Hilton.com
- [Pre-Conference Courses](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/ancillary-courses/): The NLA's Foundations of Lipidology course provides an introductory review of the core curriculum in Clinical Lipidology. This course is designed for any healthcare professional seeking to learn the fundamentals of Lipidology. Experts in Lipidology will lecture on basic concepts and guide participants through interactive learning scenarios that provide the knowledge and tools necessary to work effectively in a lipid practice and prepare for advanced training.
- [Expert Theaters](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/expert-theaters/): Expert Theaters are industry supported, non CME educational sessions held during designated breaks in the official meeting schedule. These focused programs feature thought leaders and clinical experts who dive into timely topics in lipid management, cardiovascular risk reduction, and emerging therapies.
- [Agenda](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/agenda/): Pre-Conference Courses (Separate Registration Required)7:00 AM-6:00 PM
- [Fall Clinical Lipid Update](https://www.lipid.org/conferences/2026-fall-clinical-lipid-update/): The go-to weekend for practical, evidence-based lipid care – built for clinicians who want what’s next and what works Monday morning.
- [Scientific Sessions](https://www.lipid.org/conferences/scientific-sessions/): Get ready for four unforgettable days in the heart of Nashville at the 2027 #NLASessions! This is the premier meeting for lipidology and cardiometabolic health, where the latest science, clinical updates, and expert insights come together.

## A. Resource Types
- [Articles](https://www.lipid.org/resource-types/article/)
- [Infographics](https://www.lipid.org/resource-types/infographics/)
- [Podcasts](https://www.lipid.org/resource-types/podcast/)
- [Videos & Webinars](https://www.lipid.org/resource-types/videos-webinars/)

## C. Clinical Sources
- [Clinical Source Infographics](https://www.lipid.org/clinical-source/clinical-resource-infographics/)
- [Expert Clinical Consensus](https://www.lipid.org/clinical-source/clinical-consensus/)
- [Expert Clinical Reviews](https://www.lipid.org/clinical-source/clinical-reviews/)
- [Lipid Simplified Series](https://www.lipid.org/clinical-sources/simplified-series/)
- [Scientific Statements](https://www.lipid.org/clinical-source/clinical-statements/)

## B. Topics
- [Abetalipoproteinemia](https://www.lipid.org/topics/disorders/abetalipoproteinemia-disorders/)
- [ApoB](https://www.lipid.org/topics/fundamentals/lipoproteins-apolipoproteins-fundamentals/ldl-lipoproteins-apolipoproteins/apob-ldl/)
- [ApoC3 inhibitors](https://www.lipid.org/topics/management/therapy-management/apoc3-inhibitors-tg-lowering/)
- [ApoE](https://www.lipid.org/topics/fundamentals/lipoproteins-apolipoproteins-fundamentals/apoe/)
- [ASCVD](https://www.lipid.org/topics/disorders/ascvd-disorders/)
- [Bempedoic Acid](https://www.lipid.org/topics/management/therapy-management/bempedoic-acid/)
- [CAC](https://www.lipid.org/topics/fundamentals/imaging-prevention/cac-imaging/)
- [Cardiometabolic Disorders](https://www.lipid.org/topics/disorders/cardiometabolic-disorders-disorders/)
- [Cholesterol & Triglycerides](https://www.lipid.org/topics/fundamentals/cholesterol-fundamentals/)
- [Chronic Kidney Disease (CKD)](https://www.lipid.org/topics/disorders/chronic-kidney-disease-ckd/)
- [Chylomicronemia](https://www.lipid.org/topics/disorders/chylomicronemia-disorders/)
- [Chylomicrons](https://www.lipid.org/topics/fundamentals/lipoproteins-apolipoproteins-fundamentals/chylomicrons-lipoproteins-apolipoproteins/)
- [CTA](https://www.lipid.org/topics/fundamentals/imaging-prevention/cta-imaging/)
- [CTX](https://www.lipid.org/topics/disorders/ctx-disorders/)
- [Diabetes](https://www.lipid.org/topics/disorders/cardiometabolic-disorders-disorders/diabetes-cardiometabolic-disorders/)
- [Disorders](https://www.lipid.org/topics/disorders/)
- [Elevated Lp(a)](https://www.lipid.org/topics/disorders/lipid-disorders/elevated-lpa/)
- [Ezetimibe](https://www.lipid.org/topics/management/therapy-management/ezetimibe/)
- [Familial Hypercholesterolemia](https://www.lipid.org/topics/disorders/familial-hypercholesterolemia/)
- [Fibrates](https://www.lipid.org/topics/fibrates/)
- [Foundational Lipidology](https://www.lipid.org/topics/fundamentals/)
- [Geriatric](https://www.lipid.org/topics/management/geriatric-management/)
- [Glucagon-Like Peptide-1 (GLP-1) agonists](https://www.lipid.org/topics/fundamentals/glucagon-like-peptide-1-glp-1/)
- [HDL/HDL-C](https://www.lipid.org/topics/fundamentals/lipoproteins-apolipoproteins-fundamentals/hdl-lipoproteins-apolipoproteins/)
- [Hypertriglyceridemia](https://www.lipid.org/topics/disorders/hypertriglyceridemia-disorders/)
- [Icosapent Ethyl](https://www.lipid.org/topics/management/therapy-management/icosapent-ethyl/)
- [Imaging](https://www.lipid.org/topics/prevention/imaging-prevention/)
- [LAL-D](https://www.lipid.org/topics/disorders/lal-d-disorders/)
- [LDL / LDL-C](https://www.lipid.org/topics/fundamentals/lipoproteins-apolipoproteins-fundamentals/ldl-lipoproteins-apolipoproteins/)
- [Lifestyle](https://www.lipid.org/topics/prevention/lifestyle-management/)
- [Lipid Disorders](https://www.lipid.org/topics/disorders/lipid-disorders/)
- [Lipids & Dyslipidemia](https://www.lipid.org/topics/fundamentals/lipids-dyslipidemia/)
- [Lipodystrophy](https://www.lipid.org/topics/disorders/lipodystrophy-disorders/)
- [Lipoprotein Apheresis](https://www.lipid.org/topics/management/therapy-management/lipoprotein-apheresis/)
- [Lipoprotein X](https://www.lipid.org/topics/disorders/lipoprotein-x-disorders/)
- [Lipoproteins + Apolipoproteins](https://www.lipid.org/topics/fundamentals/lipoproteins-apolipoproteins-fundamentals/)
- [Lp(a)](https://www.lipid.org/topics/fundamentals/lipoproteins-apolipoproteins-fundamentals/ldl-lipoproteins-apolipoproteins/lpa-ldl/)
- [Management of Disorders](https://www.lipid.org/topics/management/)
- [MASLD](https://www.lipid.org/topics/disorders/cardiometabolic-disorders-disorders/masld-cardiometabolic-disorders/)
- [Metabolic Syndrome & Insulin Resistance](https://www.lipid.org/topics/disorders/cardiometabolic-disorders-disorders/metabolic-syndrome-insulin-resistance-cardiometabolic-disorders/)
- [Multidisciplinary Team Care](https://www.lipid.org/topics/fundamentals/multidisciplinary-team-care/)
- [Niacin](https://www.lipid.org/topics/management/therapy-management/niacin/)
- [Nutrition](https://www.lipid.org/topics/management/lifestyle-management/nutrition-lifestyle/)
- [Omega-3 Fatty Acids](https://www.lipid.org/topics/management/therapy-management/high-dose-omega-3-fatty-acids-tg-lowering/)
- [Overweight & Obesity](https://www.lipid.org/topics/disorders/cardiometabolic-disorders-disorders/obesity-cardiometabolic-disorders/)
- [PCSK9 Inhibitors](https://www.lipid.org/topics/pcsk9-inhibitors/)
- [Pediatrics](https://www.lipid.org/topics/management/pediatrics-management/)
- [Pharmacotherapies](https://www.lipid.org/topics/management/therapy-management/)
- [PREVENT-ASCVD Risk Calculator](https://www.lipid.org/topics/fundamentals/ascvd-disorders/primary-prevention/ascvd-risk-equations-prevention/prevent-ascvd-risk-equations/)
- [Primary Prevention](https://www.lipid.org/topics/fundamentals/ascvd-disorders/primary-prevention/)